FDA fast-tracks lecanemab for Alzheimer’s diseaseJune 25, 2021Alzheimer's & CognitionNeurologyGeriatrics
FDA leader explains rationale leading to controversial Alzheimer’s drug approvalJune 25, 2021Alzheimer's & CognitionNeurology
No overall statin effect seen on dementia, cognition in ASPREE analysisJune 23, 2021DiabetesObesityCardiologyAlzheimer's & Cognition
Memory benefit seen with antihypertensives crossing blood-brain barrierJune 21, 2021NeurologyCardiologyGeriatricsMental HealthMixed TopicsAlzheimer's & Cognition
Is trouble falling asleep a modifiable risk factor for dementia?June 21, 2021Sleep MedicineAlzheimer's & CognitionNeurology
Watchdog group demands removal of FDA leaders after aducanumab approvalJune 16, 2021Alzheimer's & CognitionNeurologyGeriatrics
Photobiomodulation: Evaluation in a wide range of medical specialties underwayJune 16, 2021PainOncologyNeurologyAlzheimer's & CognitionMixed Topics
FDA approves controversial Alzheimer’s drug aducanumab (Aduhelm)June 7, 2021Alzheimer's & CognitionNeurologyGeriatrics
The end of happy hour? No safe level of alcohol for the brainMay 25, 2021Addiction MedicineAlzheimer's & CognitionNeurologyMixed Topics
Rituximab benefits seen in neuropsychiatric lupusApril 29, 2021RheumatologyNeurologyAlzheimer's & Cognition
Age-related cognitive decline not inevitable?April 7, 2021GeriatricsMental HealthNeurologyAlzheimer's & Cognition
Despite risks and warnings, CNS polypharmacy is prevalent among patients with dementiaMarch 16, 2021Alzheimer's & CognitionNeurology
Novel Alzheimer’s drug slows cognitive decline in phase 2 trialMarch 16, 2021Alzheimer's & CognitionNeurologyMental HealthGeriatrics
